Gross P A, Lee H, Wolff J A, Hall C B, Minnefore A B, Lazicki M E
J Pediatr. 1978 Jan;92(1):30-5. doi: 10.1016/s0022-3476(78)80065-1.
Optimal influenza immunization of individuals with malignancy and other immunodeficient states requires and understanding of responses to currently recommended regimens. Children with acute lymphocytic leukemia and other malignancies between three and 17 years of age were immunized with bivalent influenza vaccine containing A/New Jersey/76 and A/Victoria/75. Folowing a two-dose immunization schedule, only 37% (25468) on cancer chemotherapy seroconverted to a hemagglutination inhibition titer greater than or equal to 20 for A/NJ/76; the seroconversion rate in those not on chemotherapy was 92% (68/74, P less than 0.001). The immune response to the A/Vic/75 antigen was also related to a history of recent chemotherapy. There was no correlation between the immune response and the peripheral white blood cell count except at counts less than or equal to 1,000. The optimum time to immunize children with malignancies is when they have been off chemotherapy for one month and have peripheral white blood counts greater than 1,000.
对患有恶性肿瘤和其他免疫缺陷状态的个体进行最佳流感免疫,需要了解对当前推荐方案的反应。3至17岁的急性淋巴细胞白血病和其他恶性肿瘤患儿接种了含有A/新泽西/76和A/维多利亚/75的二价流感疫苗。按照两剂免疫程序,接受癌症化疗的患者中只有37%(25/46)的人对A/NJ/76的血凝抑制效价血清转化至大于或等于20;未接受化疗的患者血清转化率为92%(68/74,P<0.001)。对A/Vic/75抗原的免疫反应也与近期化疗史有关。除白细胞计数小于或等于1000时外,免疫反应与外周白细胞计数之间无相关性。对患有恶性肿瘤的儿童进行免疫的最佳时间是他们停止化疗一个月且外周白细胞计数大于1000时。